Welcome to our dedicated page for Immunocore Holdings plc SEC filings (Ticker: IMCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunocore Holdings plc filings document the formal disclosures of an England and Wales biotechnology company with American Depositary Shares, each representing one ordinary share, listed on Nasdaq. Recent 8-K reports furnish quarterly and annual financial results, preliminary liquidity information and corporate updates through press-release exhibits.
The filing record also includes proxy materials for the annual general meeting, covering shareholder voting procedures for ordinary shares and ADSs, and Item 5.02 disclosure on R&D leadership changes and related organizational structure. These documents describe the company’s ADS and ordinary-share capital framework, governance processes, executive matters and material-event reporting tied to its commercial-stage ImmTAX platform business.
Immunocore Holdings plc has a significant institutional holder, Vestal Point Capital, LP, which, together with Ryan Wilder, reports beneficial ownership of 1,800,000 American Depository Shares (ADS). These ADS each represent one ordinary share of Immunocore.
This position represents 3.5% of Immunocore’s outstanding shares, based on 50,865,574 shares, including ADS, outstanding as of April 30, 2026, as reported by the company. Vestal Point Capital and Ryan Wilder report shared voting and shared dispositive power over all 1,800,000 ADS, with no sole voting or dispositive power. The filing also notes that the investors now hold 5% or less of the class, and includes standard language that the reporting persons do not admit to being beneficial owners for all legal purposes.
Immunocore Holdings plc is reported to have a significant shareholder group led by Wellington Management Group LLP and related entities. They collectively report beneficial ownership of 5,959,773 shares of Immunocore common stock, representing 11.57% of the class as of June 30, 2026. The group reports no sole voting or dispositive power, with all authority held on a shared basis across the Wellington entities. The securities are owned of record by clients of Wellington’s investment advisers, who have the economic rights to dividends and sale proceeds, including Vanguard Health Care Fund, which holds more than five percent of the class through these arrangements.
FMR LLC and Abigail P. Johnson report their beneficial ownership of Immunocore Holdings plc common stock on an amended Schedule 13G. FMR LLC reports beneficial ownership of 4,307,246 shares of common stock, representing 8.8% of the class. These shares are held with sole dispositive power and no shared voting or dispositive power.
Abigail P. Johnson is reported as having sole dispositive power over the same 4,307,246 shares, also representing 8.8% of the outstanding common stock, with no voting or shared dispositive power. One or more other persons have rights to receive dividends or sale proceeds from these securities, but no such person holds more than five percent of the class.
Immunocore Holdings plc delivered solid top-line growth driven by KIMMTRAK. Net revenue from sale of therapies reached $115.9 million in the quarter ended June 30, 2026, up 18.3% year over year, and $222.6 million for the first half, a 16.0% increase.
The company generated first-half net income of $12.2 million versus a loss a year earlier, though it recorded a modest $0.8 million quarterly net loss as investment remained high. R&D expenses were $73.9 million and SG&A $43.9 million in the quarter; R&D for the half-year totaled $135.1 million, reflecting multiple Phase 3 and early-stage programs.
Liquidity is strong with $484.9 million in cash and cash equivalents and $395.3 million in marketable securities as of June 30, 2026, alongside $402.5 million of 2.50% convertible senior notes due 2030. Management highlights progress in late-stage tebentafusp and PRAME-targeted brenetafusp trials, as well as HIV candidate IMC‑M113V and autoimmune candidate IMC‑S118AI.
Immunocore Holdings reported Q2 2026 KIMMTRAK net product revenue of $115.9 million, up 18% year over year, with sales of $74.9 million in the US, $34.1 million in Europe and $6.9 million in international markets. Net loss narrowed to $0.8 million in the quarter, and the company generated $12.2 million net income for the first half of 2026.
R&D spending was $73.9 million in Q2 as three Phase 3 studies advanced. Cash, cash equivalents and marketable securities totaled $880.2 million as of June 30, 2026, compared with $864.2 million at year-end 2025; the company expects to pay about $120 million in sales-related rebate accruals in the second half of 2026.
Five-year data from the Phase 3 KIMMTRAK trial in metastatic uveal melanoma showed overall survival of 16% at five years versus 8% for control, with median overall survival of 21.6 vs 16.9 months. Enrollment is nearing completion in the Phase 3 TEBE-AM trial in previously treated cutaneous melanoma, the PRISM-MEL-301 Phase 3 trial is enrolling first-line cutaneous melanoma patients, and the pipeline also includes PRAME-targeting brenetafusp studies, an HIV program (IMC‑M113V) and autoimmune candidates such as IMC‑S118AI.
Immunocore Holdings plc director Peter John Ratcliffe received a new stock option grant. On May 27, 2026, he was granted options over 27,492 ordinary shares at an exercise price of $28.52 per share, with no cash paid for the grant itself.
The options expire on May 26, 2036 and represent his entire reported option position of 27,492 options following this transaction. According to the terms, the award will vest at the earlier of May 27, 2027 or the day immediately prior to Immunocore’s next annual general meeting, provided he continues in service through the vesting date.
Immunocore Holdings plc reported that director Kristine Peterson received a stock option grant covering 27,492 ordinary shares. The options have an exercise price of $28.52 per share and expire on May 26, 2036. The award vests at the earlier of May 27, 2027 or the day immediately prior to the company’s next annual general meeting, contingent on her continued service. This is a compensation-related award rather than an open-market share purchase or sale.
Immunocore Holdings plc director William Pao received a new stock option grant. The award covers 27,492 options to buy Ordinary Shares at an exercise price of $28.52 per share, expiring on May 26, 2036.
The options vest at the earlier of May 27, 2027, or the day immediately before Immunocore’s next annual general meeting, as long as Pao remains in continuous service through the vesting date. Following this grant, he holds 27,492 share options directly.
Immunocore Holdings plc director Siddharth Kaul received a grant of share options for 27,492 ordinary shares. The options carry an exercise price of $28.52 per share and expire on May 26, 2036, providing long-term equity-based compensation.
The award vests at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, as long as Kaul remains in continuous service until that vesting date. This is a compensation-related grant, not an open-market share purchase or sale.
Immunocore Holdings plc director Roy Steven Herbst received a grant of 27,492 share options to buy ordinary shares. The options have an exercise price of $28.52 per share and expire on May 26, 2036, according to the Form 4.
The award vests at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, provided he remains in continuous service through the vesting date. After this grant, the filing shows 27,492 derivative securities held directly.